KAI vs RARE · P/E 36, rev $594.4M vs rev $350.0M
Kadant Inc (KAI) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Kadant Inc (KAI) is a specialty industrial machinery company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported KAI revenue for 2026-07-04 was $594.4M. Net income was $58.0M. KAI currently screens at market cap $3.69B and trailing P/E 35.6.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
KAI currently screens at market cap $3.69B and trailing P/E 35.6. RARE currently screens at market cap $2.79B.
Not investment advice. Open the KAI and RARE stock pages for the full models.
Not investment advice.